Sunpointe LLC Makes New $285,000 Investment in Stryker Co. (NYSE:SYK)

Sunpointe LLC acquired a new position in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 789 shares of the medical technology company's stock, valued at approximately $285,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $36,000. Activest Wealth Management acquired a new position in shares of Stryker during the 4th quarter worth approximately $36,000. Crews Bank & Trust acquired a new position in shares of Stryker during the 4th quarter worth approximately $39,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of SYK stock traded down $3.82 on Friday, hitting $382.59. 1,268,413 shares of the company's stock were exchanged, compared to its average volume of 1,388,856. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market cap of $145.99 billion, a P/E ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a 50 day moving average of $377.92 and a 200 day moving average of $368.21.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. On average, equities research analysts predict that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's dividend payout ratio is presently 43.30%.

Analysts Set New Price Targets

SYK has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. The Goldman Sachs Group upped their price objective on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a report on Thursday, January 30th. Citigroup upped their price objective on Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Finally, Evercore ISI upped their price objective on Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $420.68.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.